Related Experiment Video
Updated: Jun 15, 2026

Rapid and Specific Detection of Acinetobacter baumannii Infections Using a Recombinase Polymerase Amplification/Cas12a-based System
Published on: April 25, 2025
[Activity of doripenem against Pseudomonas spp. and Acinetobacter spp. rods]
Tomasz Bogiel1, Aleksander Deptuła, Eugenia Gospodarek
1Katedra i Zakład Mikrobiologii Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy.
Abstract:
Doripenem, the newest carbapenem was approved in 2008 by the European Medicines Agency for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. Its spectrum of activity is similar to that of meropenem and imipenem/cilastatin. The aim of this study was to compare in vitro activity of doripenem against nonfermentative Gram-negative rods. A total of 235 strains of Pseudomonas spp. (74.9%) and Acinetobacter spp. (25.1%) were included into the study. Strains were isolated in The Department of Clinical Microbiology of the University Hospital No 1 in Bydgoszcz and identified using ID GN tests (bioMérieux). To determine susceptibility to doripenem and other carbapenems disc-diffusion method was applied. Percentage of doripenem resistant strains reached 28.4% and 39.0% for Pseudomonas spp. and Acinetobacter spp, respectively. All doripenem sensitive or intermediate Acinetobacter spp. strains were simultaneously sensitive to imipenem and meropenem. Activity of imipenem and meropenem among doripenem resistant Acinetobacter spp. were represented by 60.9% and 56.5% strains, respectively. Activity of imipenem and meropenem among doripenem resistant Pseudomonas spp. strains were represented by 12.0% and 18.0%, respectively. Occurence of one doripenem sensitive Pseudomonas spp. strain simultaneously resistant to imipenem and meropenem was observed.
Insights
Doripenem shows significant resistance in Pseudomonas and Acinetobacter species. This study compared doripenem
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Doripenem, a carbapenem antibiotic, approved in 2008 for specific infections.
- Its activity spectrum is comparable to meropenem and imipenem/cilastatin.
- Nonfermentative Gram-negative rods are significant pathogens in hospital-acquired infections.
Purpose of the Study:
- To evaluate the in vitro activity of doripenem against Pseudomonas and Acinetobacter species.
- To compare doripenem resistance rates with other carbapenems.
- To assess cross-resistance patterns between doripenem and other carbapenems.
Main Methods:
- In vitro susceptibility testing using the disc-diffusion method.
- Inclusion of 235 strains: 74.9% Pseudomonas spp. and 25.1% Acinetobacter spp.
- Bacterial identification using ID GN tests (bioMérieux).
Main Results:
- High doripenem resistance rates observed: 28.4% in Pseudomonas spp. and 39.0% in Acinetobacter spp.
- All susceptible/intermediate Acinetobacter spp. were also susceptible to imipenem and meropenem.
- Significant activity of imipenem and meropenem against resistant strains, but with notable exceptions.
Conclusions:
- Emerging resistance to doripenem in Pseudomonas and Acinetobacter necessitates careful monitoring.
- Cross-resistance patterns vary, with some susceptible strains showing resistance to other carbapenems.
- Further investigation into resistance mechanisms and clinical implications is warranted.
Related Concept Videos
Antimicrobial Effectiveness
Acute Pyelonephritis II: Diagnostic Studies and Management
Clinical Significance of Antibiotic Resistance
Hand hygiene
Hand washing...